Department of Breast Surgery, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, No.1630 Dongfang Road, Shanghai 200127, PR China.
Future Oncol. 2019 May;15(15):1781-1789. doi: 10.2217/fon-2018-0666. Epub 2019 Mar 22.
Benefit of longer course of taxane-anthracycline-based adjuvant chemotherapy is yet to be identified. We conducted a retrospectively matched-pair analysis to compare four cycles of fluorouracil, epirubicin and cyclophosphamide followed by four cycles of docetaxel (4FEC-4T) with three cycles of FEC followed by three cycles of docetaxel (3FEC-3T) as adjuvant chemotherapy for early-stage breast cancer. One hundred and thirty-seven patients treated with 4FEC-4T were matched to 411 in 3FEC-3T. The primary end point was event-free survival (EFS). The secondary end point was distant disease-free survival (DDFS). The 4FEC-4T resulted in significantly longer EFS than matched 3FEC-3T (p = 0.020). Furthermore, DDFS was superior in the 4FEC-4T to that in the 3FEC-3T (p = 0.046). Extending taxane-anthracycline-based regimens with identical schedules significantly improves EFS and DDFS for early-stage breast cancer.
更长疗程的紫杉烷类-蒽环类辅助化疗的获益尚待确定。我们进行了一项回顾性配对分析，比较了氟尿嘧啶、表柔比星和环磷酰胺 4 个周期序贯多西他赛 4 个周期（4FEC-4T）与氟尿嘧啶、表柔比星 3 个周期序贯多西他赛 3 个周期（3FEC-3T）作为早期乳腺癌辅助化疗的疗效。137 例接受 4FEC-4T 治疗的患者与 3FEC-3T 中的 411 例患者相匹配。主要终点是无事件生存（EFS）。次要终点是远处无病生存（DDFS）。4FEC-4T 的 EFS 明显长于匹配的 3FEC-3T（p=0.020）。此外，4FEC-4T 的 DDFS 优于 3FEC-3T（p=0.046）。用相同方案延长紫杉烷类-蒽环类方案可显著提高早期乳腺癌的 EFS 和 DDFS。
